CompletedNot Applicable

Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections

Denmark61 participantsStarted 2019-06-03

Plain-language summary

The purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent form
✓. Has a single-lumen subcutaneously tunneled CVC
✓. Has been at least 3 weeks since termination of the antibiotic treatment for their last CRBSI

Exclusion criteria

✕. have a known hypersensitivity/allergy to TauroLockTMHep 100 or heparin and/or their excipients
✕. are pregnant, lactating or nursing

What they're measuring

Incidence of recurrent catheter-related bloodstream infections

Timeframe: Treatment time 2 years

Trial details

NCT IDNCT06660641

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-28

View on ClinicalTrials.gov More Catheter Related Blood Stream Infections trials